Sunday, 29. February 2004
 

12:30 - 14:00	Registration
Opening
14:00 - 14:30	Ulf R. Rapp Chairman of BioMedTec Franken e.V. Pia Beckmann Lord Mayor of Würzburg State Secretary Emilia Müller Bavarian State Ministry for Regional Development and Environmental Affairs
Keynote Lectures Chair: Ulf R. Rapp
14:30 - 15:30	Brett Finlay Vancouver	Innate immunity and infectious diseases
15:30 - 16:30	Antonio Coutinho Oeiras	If self-tolerance is dominant, Immune Therapy requires radically different approaches
16:30 - 17:00	Coffee break and Industrial Exhibition
Biotechnology for Immune Therapy Chair: Stephan Schröder-Köhne
17:00 - 18:30	Joachim Fensterle, TheraImmune GmbH	Bacteria as immunotherapeutics against tumors
	Thomas Hanke, TeGenero AG	Superagonistic monoclonal antibodies: a novel and unique approach towards therapy of immunological diseases
	Frank Hensel, OncoMab GmbH	Natural IgM antibodies as therapeutic tools for epithelial cancer
	Eckhart Kämpgen, MerixGmbH	Validation and GMP production of autologous Mage-3, MelanA and Survivin expressing RNA-DC vaccines suitable for broad immunotherapy of melanoma
	Jürgen Hess, responsif  GmbH	Novel immunotherapeutic concepts against cancer
18:45	Welcome Reception "Haus des Frankenweins"

 

Monday, 01. March 2004
 

08:00 - 11:00	Registration
Session 1 The Cell Biology of Immune Therapy
Part 1: Cells of the Immune System Chair: Pamela Ohashi 09:00 - 10:30
	Jeffrey A. Frelinger Chapel Hill	Affinity/Avidity and co-receptors: CD8, rheostats for T cells?
	Guiseppe Pantaleo Lausanne	Immune response to HIV
	Bruno Kyewski Heidelberg	T-cell tolerance to tumor-associated self antigens: implications for tumor therapy?
10:30 - 11:00	Coffee break and Industrial Exhibition
Part 2: Host-Pathogen Interaction Chair: Jörg Hacker 11:00 - 12:30
	Cesare Montecucco Padua	Toxic and inflammatory activities of virulence factors of Helicobacter pylori
	Jürgen Heesemann Munich	The antiphlogistic strategy of Yersinia
	Matthias Frosch Würzburg	From population structure of meningococci to pathogenesis and vaccine design
12:30 - 13:00	Short Talks
	Carl Friedrich Classen Ulm	Role of the granzyme B inhibitor PI-9 in lymphocytes and antigen-presenting cells
	Stephan Sudowe Mainz	Transcriptional targeting of dendritic cells – a promising strategy to improve the efficiency of DNA vaccines
	Holger Barth Freiburg	The host cell chaperone HSP90 is essential for cellular uptake of clostridial binary actin-ADP-ribosylating toxins
13:00 - 14:30	Lunch-Break and Industrial Exhibition Official Poster Session
Part 3: Tumor Cells: Interaction with their Environment and Immune Cells Chair: Eva-B. Bröcker 14:30 - 16:00
	Pamela Ohashi Toronto	Natural immune surveillance versus induced anti-tumor immunity: insights for immunotherapy
	Hans Schreiber Chicago	Targeting tumor stroma to prevent cancer escape
	Van den Eynde Brussels	A new mechanism of tumor immune resistance based on tryptophan degradation by indoleamine 2 ,3-dioxygenase
16:00 - 16:30	Coffee break and Industrial Exhibition
Chair: Jeffrey Frelinger 16:30 - 18:00
	Thomas Blankenstein Berlin	The Achilles heel of the tumor
	Günter Hämmerling Heidelberg	The endothelial barrier. Towards a novel concept for the immunotherapy of cancer
	Peter Krammer Heidelberg	CD95(APO-1/FAS) Signalling and Diseases
18:30 - 19:00	Short Talks
	Maja Zeidler Mainz	Parvovirus H1-induced tumor cell death enhances human immune response via crosspresentation of dendritic cells
	Marco Bueter Würzburg	Investigation of a possible escape mechanism in colorectal cancer patients
	Martin Gasser Würzburg	Comparison of p53 antibody status and carcinoembryonic antigen (CEA) levels and their clinical impact as diagnostic markers in colorectal cancer patients
19:30	public lecture Jürgen Becker Würzburg	Zukunftsvision Immuntherapie: Neue Behandlungsformen gegen den Schwarzen Hautkrebs?
19:45	Welcome Reception in the Historic Town Hall of Würzburg

 

Tuesday, 02. March 2004
 

08:00 - 9:00	Registration
Session 2 Vaccines
Part 1: Vaccines against Infectious Pathogens Chair: Heidrun Moll 08:30 - 10:30
	Xavier Nassif Paris	Identification of new bacterial antigens by a combination of reverse epidemiology and comparative genomics
	Bernard Moss Bethesda	Safer Smallpox Vaccines
	Rino Rappuoli Siena	Reverse Vaccinology
	Stefan H.E. Kaufmann Berlin	Rational Vaccination against Tuberculosis
10:30 - 11:00	Coffee break and Industrial Exhibition
Chair: Thomas Hünig 11:00 - 12:30
	Aladar Szalay Würzburg	Visualization of Tumors and Metastasis in Live Animals with Light Emitting Bacteria and Vaccinia Viruses
	Heidrun Moll Würzburg	Dendritic cells as a tool to combat infectious diseases
	Yasir Skeiky Bethesda	Immune Responses and Protective Efficacy of a Multi-subunit Tuberculosis Vaccine Delivered as Naked DNA or Recombinant Protein.
12:30 - 13:00	Short Talks
	Ralf Wagner Regensburg	RNA and Codon-optimised Synthetic Genes in HIV specific DNA Vaccination: From epidemiology to clinical trials
	Kurt Bieler Regensburg	Containment of SHIV89.6P Infection in Rhesus Macaques after DNA/MVA Immunization: Influence of Application Strategies and Vaccine Components
	Henning Lauterbach Munich	Recombinant Herpes simplex virus type 1 vectors induce protective immune responses against Listeria monocytogenes but the vaccine efficacy is strongly affected by preexisting host immunity
13:00 - 14:30	Lunch-Break and Industrial Exhibition
13:15 - 14:15	Workshop IBA GmbH: Streptamers - new MHC multimer reagents for immunotherapies
Part 2: Tumor Vaccines Chair: Ulf R. Rapp 14:30 - 16:00
	Volker Schirrmacher Heidelberg	An effective strategy of human tumor vaccine modification by virus infection and coupling of bispecific T cell stimulatory molecules to deliver three signal T cell activation
	Federica Cavallo Turin	DNA Vaccination in Tumor Prevention
	Yvonne Paterson Philadelphia	What immune parameters correlate with effective anti-tumor immunotherapy? Lessons learned using Listeria monocytogenes as a live vector for HPV associated tumors
16:00 - 16:30	Coffee break and Industrial Exhibition
Chair: Jürgen Becker
	Thomas Wölfel Mainz	Molecular Targets of the Anti-Tumor T Cell Response
	Elke Jäger Frankfurt a.M.	NY-ESO-1 specific immune responses in cancer patients
	Stefan Stevanovic Tübingen	Lessons from a solid tumor
18:00 - 18:30	Short Talks
	Steve Pascolo Tübingen	Immune therapies based on direct injection of GMP- quality stabilised messenger RNA
	Sergey Severin Moscow	Preventive vaccination of mice with human melanoma cells injected into subcutaneously encapsulated polyacrylamide gel
	Lothar Kaiser Aschaffenburg	A phase I/II study of vaccination with tumor-lysate pulsed dendritic cells in patients with metastatic renal cell cancer
19:30	Banquet Residenz

 

Wednesday, 03 . March 2004
 

08:00 - 09:00	Registration
Session 3 Non-Vaccine Approaches in Immune Therapy Chair: Hans Schreiber 08:15 - 11:15
	Arthur M. Krieg Wellesley	Immune therapeutic applications of stimulating TLR9 with B-Class and C-Class CpG oligos
	Hermann Wagner Munich	Immunobiology of the TLR7, TLR8 and TLR9 subfamily
	Hans Wolf Regensburg	Development of HIV vaccines: Mastering constraints from molecular pathogenesis and financing systems
09:45 - 10:15	Coffee break and Industrial Exhibition
	Jens Hennecke Munich	Induction of a polyclonal T Cell Response for Human Therapy
	Stefan Ries Martinsried	Oncolytic HSV as in situ Vaccine for the Treatment of Cancer
11:15 - 11:45	Short Talks
	Karl-Hermann Schlingensiepen Regensburg	Specific therapy for high-grade glioma by convection-enhanced delivery of the TGF-beta2 specific antisense oligonucleotide AP 12009
	Chris Reading San Diego	Immune Regulating Steroid Hormones
	Dorothee von Laer Frankfurt	Immuno-Gene Therapy for HIV Infection
11:15	Concluding Remarks

Note:
The organisers reserve the right to alter the program without prior announcement, if necessary. If an event is cancelled, the organisers are not responsible for airfare, hotel or other costs incurred by registrants.